Logo image of AVNS

AVANOS MEDICAL INC (AVNS) Stock Fundamental Analysis

NYSE:AVNS - New York Stock Exchange, Inc. - US05350V1061 - Common Stock - Currency: USD

12.3  -0.25 (-1.99%)

Fundamental Rating

4

AVNS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. AVNS has an average financial health and profitability rating. AVNS has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year AVNS was profitable.
In the past year AVNS had a positive cash flow from operations.
In multiple years AVNS reported negative net income over the last 5 years.
Of the past 5 years AVNS 4 years had a positive operating cash flow.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

AVNS has a Return On Assets (-33.97%) which is comparable to the rest of the industry.
With a Return On Equity value of -47.33%, AVNS perfoms like the industry average, outperforming 49.74% of the companies in the same industry.
With a decent Return On Invested Capital value of 3.57%, AVNS is doing good in the industry, outperforming 73.55% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AVNS is significantly below the industry average of 7.68%.
The last Return On Invested Capital (3.57%) for AVNS is above the 3 year average (2.58%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -33.97%
ROE -47.33%
ROIC 3.57%
ROA(3y)-11.6%
ROA(5y)-7.22%
ROE(3y)-16.14%
ROE(5y)-10.03%
ROIC(3y)2.58%
ROIC(5y)N/A
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

AVNS has a better Operating Margin (6.50%) than 74.07% of its industry peers.
AVNS's Operating Margin has improved in the last couple of years.
AVNS has a Gross Margin (55.44%) which is comparable to the rest of the industry.
AVNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.5%
PM (TTM) N/A
GM 55.44%
OM growth 3Y42.57%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5Y-0.78%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AVNS is destroying value.
The number of shares outstanding for AVNS has been reduced compared to 1 year ago.
The number of shares outstanding for AVNS has been reduced compared to 5 years ago.
AVNS has a worse debt/assets ratio than last year.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

AVNS has an Altman-Z score of 1.17. This is a bad value and indicates that AVNS is not financially healthy and even has some risk of bankruptcy.
AVNS has a Altman-Z score (1.17) which is in line with its industry peers.
AVNS has a debt to FCF ratio of 1.62. This is a very positive value and a sign of high solvency as it would only need 1.62 years to pay back of all of its debts.
AVNS's Debt to FCF ratio of 1.62 is amongst the best of the industry. AVNS outperforms 90.48% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that AVNS is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.15, AVNS perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 1.62
Altman-Z 1.17
ROIC/WACC0.4
WACC8.96%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 2.37 indicates that AVNS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.37, AVNS is in line with its industry, outperforming 42.86% of the companies in the same industry.
AVNS has a Quick Ratio of 1.53. This is a normal value and indicates that AVNS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.53, AVNS is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 1.53
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for AVNS have decreased by -8.70% in the last year.
AVNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.32% yearly.
The Revenue has been growing slightly by 2.15% in the past year.
Measured over the past years, AVNS shows a decrease in Revenue. The Revenue has been decreasing by -0.28% on average per year.
EPS 1Y (TTM)-8.7%
EPS 3Y3.09%
EPS 5Y3.32%
EPS Q2Q%31.25%
Revenue 1Y (TTM)2.15%
Revenue growth 3Y-2.61%
Revenue growth 5Y-0.28%
Sales Q2Q%3.64%

3.2 Future

Based on estimates for the next years, AVNS will show a small growth in Earnings Per Share. The EPS will grow by 5.00% on average per year.
AVNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.65% yearly.
EPS Next Y-8.93%
EPS Next 2Y1.4%
EPS Next 3Y5%
EPS Next 5YN/A
Revenue Next Year-1.74%
Revenue Next 2Y0.78%
Revenue Next 3Y1.65%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.76, the valuation of AVNS can be described as very reasonable.
Based on the Price/Earnings ratio, AVNS is valued cheaper than 94.71% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.88. AVNS is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 10.72, the valuation of AVNS can be described as reasonable.
93.12% of the companies in the same industry are more expensive than AVNS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.20, AVNS is valued a bit cheaper.
Industry RankSector Rank
PE 9.76
Fwd PE 10.72
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

AVNS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AVNS is cheaper than 96.30% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AVNS is valued cheaply inside the industry as 98.94% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.83
EV/EBITDA 6.7
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)2.94
EPS Next 2Y1.4%
EPS Next 3Y5%

More info and screens

0

5. Dividend

5.1 Amount

AVNS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVANOS MEDICAL INC

NYSE:AVNS (5/1/2025, 2:58:30 PM)

12.3

-0.25 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners96.82%
Inst Owner Change0.1%
Ins Owners2.93%
Ins Owner Change7.67%
Market Cap565.80M
Analysts45.71
Price Target17.34 (40.98%)
Short Float %2.1%
Short Ratio1.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.32%
Min EPS beat(2)-0.3%
Max EPS beat(2)2.94%
EPS beat(4)1
Avg EPS beat(4)-2.88%
Min EPS beat(4)-13.23%
Max EPS beat(4)2.94%
EPS beat(8)3
Avg EPS beat(8)4.92%
EPS beat(12)6
Avg EPS beat(12)5.7%
EPS beat(16)8
Avg EPS beat(16)4.49%
Revenue beat(2)0
Avg Revenue beat(2)-2.69%
Min Revenue beat(2)-4.72%
Max Revenue beat(2)-0.66%
Revenue beat(4)0
Avg Revenue beat(4)-1.7%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)-0.04%
Revenue beat(8)0
Avg Revenue beat(8)-2.83%
Revenue beat(12)0
Avg Revenue beat(12)-6.91%
Revenue beat(16)2
Avg Revenue beat(16)-5.26%
PT rev (1m)0%
PT rev (3m)-15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-33.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.28%
Revenue NY rev (1m)-2.74%
Revenue NY rev (3m)-5.86%
Valuation
Industry RankSector Rank
PE 9.76
Fwd PE 10.72
P/S 0.82
P/FCF 6.83
P/OCF 5.62
P/B 0.68
P/tB 2.17
EV/EBITDA 6.7
EPS(TTM)1.26
EY10.24%
EPS(NY)1.15
Fwd EY9.33%
FCF(TTM)1.8
FCFY14.65%
OCF(TTM)2.19
OCFY17.8%
SpS14.95
BVpS18.01
TBVpS5.67
PEG (NY)N/A
PEG (5Y)2.94
Profitability
Industry RankSector Rank
ROA -33.97%
ROE -47.33%
ROCE 4.52%
ROIC 3.57%
ROICexc 4.01%
ROICexgc 11.29%
OM 6.5%
PM (TTM) N/A
GM 55.44%
FCFM 12.05%
ROA(3y)-11.6%
ROA(5y)-7.22%
ROE(3y)-16.14%
ROE(5y)-10.03%
ROIC(3y)2.58%
ROIC(5y)N/A
ROICexc(3y)2.84%
ROICexc(5y)N/A
ROICexgc(3y)9.32%
ROICexgc(5y)N/A
ROCE(3y)3.26%
ROCE(5y)N/A
ROICexcg growth 3Y51.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y59.93%
ROICexc growth 5YN/A
OM growth 3Y42.57%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5Y-0.78%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 1.62
Debt/EBITDA 1.39
Cap/Depr 39.12%
Cap/Sales 2.59%
Interest Coverage 3.89
Cash Conversion 111.64%
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 1.53
Altman-Z 1.17
F-Score5
WACC8.96%
ROIC/WACC0.4
Cap/Depr(3y)39.4%
Cap/Depr(5y)44.02%
Cap/Sales(3y)2.53%
Cap/Sales(5y)2.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.7%
EPS 3Y3.09%
EPS 5Y3.32%
EPS Q2Q%31.25%
EPS Next Y-8.93%
EPS Next 2Y1.4%
EPS Next 3Y5%
EPS Next 5YN/A
Revenue 1Y (TTM)2.15%
Revenue growth 3Y-2.61%
Revenue growth 5Y-0.28%
Sales Q2Q%3.64%
Revenue Next Year-1.74%
Revenue Next 2Y0.78%
Revenue Next 3Y1.65%
Revenue Next 5YN/A
EBIT growth 1Y496%
EBIT growth 3Y38.85%
EBIT growth 5YN/A
EBIT Next Year51.47%
EBIT Next 3Y22.03%
EBIT Next 5YN/A
FCF growth 1Y467.81%
FCF growth 3Y7.73%
FCF growth 5YN/A
OCF growth 1Y210.8%
OCF growth 3Y4.87%
OCF growth 5YN/A